Eshelman Ventures, LLC
CIK 1706673 · last filed 2022-04-04
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$420.34M
Companies
3
Total Filings
19
Lifetime Open-Market Net
-$6.22M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Aravive, Inc. (ARAV) Delisted | Director | 9,211,769 | $0.04 | $369.4K | $0 | 6 | 2022-04-04 |
| LQDA | 10%+ Owner | 5,258,232 | $79.94 | $420.34M | -$10.72M | 6 | 2021-01-26 |
| G1 Therapeutics, Inc. (GTHX) Delisted | 10%+ Owner | 3,139,151 | $7.15 | $22.44M | $4.50M | 1 | 2017-05-24 |
Recent Filings · Page 2 of 2
19 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2020-11-27 | — | Sell (S) | −34,728 | -$108.7K | |
| 2020-11-25 | — | Sell (S) | −566,930 | -$1.79M | |
| 2020-11-20 | — | Disp (D) | −60,000 | -$201.0K | |
| 2020-09-15 | Aravive, Inc. (ARAV) Delisted | Grant (A) | — | $0 | EDGAR |
| 2020-06-03 | Aravive, Inc. (ARAV) Delisted | Grant (A) | — | $0 | EDGAR |
| 2020-04-07 | — | Buy (P) | +158,500 | $806.9K | |
| 2020-04-03 | — | Buy (P) | +104,446 | $511.8K | |
| 2020-04-01 | — | Buy (P) | +88,200 | $426.4K | |
| 2017-05-24 | G1 Therapeutics, Inc. (GTHX) Delisted | Mixed | +3,439,151 | $4.50M | EDGAR |
Showing 11–19 of 19
Prev
Page 2 of 2
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.